Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru

American Journal of Tropical Medicine and Hygiene

Volumn 68, Issue 1, 2003, Pages 120-123

  Marquiño, Wilmer ^a   Macarthur, John R ^d   Barat, Lawrence M ^c   Oblitas, Fernando E ^e   Arrunátegui, Manuel ^e   Garavito, Gino ^e   Chafloque, Maritza L ^e   Pardavé, Blanca ^a   Gutierrez, Sonia ^a   Arróspide, Nancy ^a   Carrillo, Carlos ^b   Cabezas, César ^a   Ruebush II, Trenton K ^d  

^a INSTITUTO NACIONAL DE SALUD   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c WORLD BANK   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e MINISTERIO DE SALUD   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CHLOROQUINE; FANSIDAR; MEFLOQUINE; ANTIMALARIAL AGENT; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD SMEAR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; GAMETOCYTE; GIEMSA STAIN; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; MULTICENTER STUDY; PARASITEMIA; PERU; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT FAILURE; ANIMAL; CHILD; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; MALARIA FALCIPARUM; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM; PROTOZOA;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; MIDDLE AGED; PERU; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 0037267843     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2003.68.120     Document Type: Article

References (20)

1. Aramburú J, Ramal C, Witzig R, 1999. Malaria reemergence in the Peruvian Amazon Region. Emerg Inf Dis 5: 209-215.
2. Ministerio de Salud, Programa de Control de la Malaria y Otras Enfermedades Metaxénicas (2000). Lima, Peru.
3. Navitsky RC, Witzig RS, Quintana Zurita J, Rios M, Aramburú Guarda JS, Gilman RH, Shankar AH, 1997. In vivo resistance of Plasmodium falciparum to pyrimethamine/sulfadoxine in children of the Amazon Region of Peru. Am J Trop Med Hyg 57 (Suppl): 229.
4. Magill AJ, Garcia C, Solari L, Ylquimiche L, Vasquez M, Carey C, Calampa C, Llanos-Cuentas A, 1999. Therapeutic efficacy of pyrimethamine-sulfadoxine in the Peruvian Amazon. Am J Trop Med Hyg 61 (Suppl): 285.
5. Stennies GM, Marquiño W, Pardavé B, Roper M, Cabezas C, Kolczak M, Pieniazek N, Kublin JG, Carrillo C, Magill A, Plowe C, Ruebush TK, 1999. Efficacy and molecular epidemiology of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum infections in the Peruvian Amazon. Am J Trop Med Hyg 61 (Suppl): 291.
6. Ministerio de Salud, (2000) Política Nacional de Medicamentos para el Control de la Malaria en el Perú, Lima, Peru.
7. Pan American Health Organization, 1998. Evaluation of the therapeutic efficacy of drugs for the treatment of uncomplicated Plasmodium falciparum malaria in the Americas. OPS/HCP/HCT/113/98. Washington, DC.
8. Lemeshow S, Tabor S, 1991. Lot quality assurance sampling: single- and double-sampling plans. World Health Stat Q 44: 115-132.
9. Bruce-Chwatt LJ, 1986. Chemotherapy of Malaria. Second edition. World Health Organization Monograph Series No. 27. Geneva: World Health Organization, pp 261.
10. Comer RD, Young MD, Porter JA, Gauld JR, Merritt W, 1968. Chloroquine resistance in Plasmodium falciparum malaria on the Pacific Coast of Colombia. Am J Trop Med Hyg 17: 795-799.
11. Osorio LE, Giraldo LE, Grajales LF, Arriaga AL, Andrade AL, Ruebush TK, Barat LM, 1999. Assessment of the therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in an area of low malaria transmission in Colombia. Am J Trop Med Hyg 61: 968-972.
12. Nwanyanwu OC, Ziba C, Macheso A, Kazembe P, 2000. Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. Trop Med Int Health 5: 355-358.
13. White NJ, 1992. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 30: 571-585.
14. de Souza JM, 1983. A phase II clinical trial of mefloquine in Brazilian male subjects. Bull WHO 61: 815-820.
15. Cardoso BS, Dourado HV, Pinheiro MCN, Crescente JAB, Amoras WW, Baena J, Saraty S, 1996. Estudo da eficácia e tolerância do artesunato oral isolado e em associação com mefloquina no tratamento da malária falciparum não complicada em área endêmica do Pará. Brasil. Ref Soc Bras Med Trop 29: 251-257.
16. Cerutti C, Durlacher RR, de Alencar FEC, Segurado AAC, Pang LW, 1999. In vivo efficacy of mefloquine for the treatment of falciparum malaria in Brazil. J Infect Dis 180: 2077-2080.
17. Bloland PB, Ettling M, 1999. Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol 93: 5-23.
18. Bloland PB, Kazembe PN, Oloo AJ, Himonga B, Barat LM, Ruebush TK, 1998. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa. Trop Med Internat Health 3: 543-552.
19. Barat LM, Himonga B, Nkunika S, Ettling M, Ruebush TK, Kapelwa W, Bloland PB, 1998. A systematic approach to the development of a rational malaria treatment policy in Zambia. Trop Med Internat Health 3: 535-542.
20. Bloland PB, Lackritz EM, Kazembe PN, Were JBO, Steketee R, Campbell CC, 1993. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167: 932-937.